
Applied BioCode Corporation
Aktie · KYG0488D1051 (XTAI)
AI-gestützte Analyse
Fundamental-Analyse
Was die Zahlen wirklich bedeuten – bevor der Markt es weiß.
Jetzt analysieren
News Sentiment
Kaufchance oder Alarmsignal? Was die aktuellen Nachrichten wirklich bedeuten.
Jetzt analysieren
Kaufen / Halten / Verkaufen
Kaufen, Halten oder Verkaufen? Das AI-Urteil auf einen Blick.
Jetzt analysieren
Risiko-Bewertung
Risiken erkennen, bevor sie zum Problem werden.
Jetzt analysieren
Fair Value
Zu teuer, fair bewertet oder ein Schnäppchen?
Jetzt analysieren
Neuste KI Analysen zu Applied BioCode Corporation
Kein Kurs
Schlusskurs XTAI 29.04.2026:
21,95 TWD
29.04.2026 05:30
Aktuelle Kurse von Applied BioCode Corporation
| Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
|---|---|---|---|---|---|
TWSE |
6598.TW
|
TWD
|
29.04.2026 05:30
|
21,95 TWD
| 0,05 TWD
+0,23 %
|
Firmenprofil zu Applied BioCode Corporation Aktie
Applied BioCode Corporation designs, develops, manufactures, and commercializes multiplex diagnostic testing products for the In-Vitro diagnostics market. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. In addition, It develops assays, such as BioCode SARS-CoV-2 Assay, a high volume automated nucleic acid multiplex assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; BioCode Respiratory Pathogen Panels, which simultaneously detects and differentiates the presence of 17 respiratory pathogens in nasopharyngeal swabs; BioCode gastrointestinal (GI) pathogen panels for common GI pathogens, including viruses, bacteria, and parasites that cause infectious diarrhea; and MDx assays pipeline for various molecular tests. Further, the company offers fungal pathogen analyte specific reagents; human cytokine/chemokine multiplex kits to identify relevant biomarkers; mouse premixed multiplex kits and custom panels for enhancing flexibility in experimental design allowing the user to pick and choose their own analytes panel; and rat, monkey, canine, and non-human primate cytokine/chemokine multiplex kits. Additionally, the company provides BMB, calibration beads, and coupling kits for various bioassay applications; ELISA, a tool for the quantitative measurement of drug/protein/antibody levels in biological samples comprising cell lysate or serum; and various assay development services. Applied BioCode Corporation is based in Santa Fe Springs, California.
Unternehmensdaten
Name Applied BioCode Corporation
Firma Applied BioCode Corporation
Website
https://www.apbiocode.com
Heimatbörse
TWSE
ISIN KYG0488D1051
Wertpapierart Aktie
Sektor Healthcare
Branche Medical - Devices
CEO Winston Z. Ho
Marktkapitalisierung 2 Mrd.
Land Vereinigte Staaten von Amerika
Währung TWD
Mitarbeiter 0,0 T
Adresse 12130 Mora Dr., 90670 Santa Fe Springs
IPO Datum 2017-02-09
Aktien-Splits
| Datum | Split |
|---|---|
| 02.07.2024 | 529:500 |
Ticker Symbole
| Name | Symbol |
|---|---|
| TWSE | 6598.TW |
Weitere Aktien
Investoren, die Applied BioCode Corporation halten, haben auch folgende Aktien im Depot:
